Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Idaho for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Idaho only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Idaho (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Danko Martincic (NPI 1124071592)

Field	Value
Entity Type	Individual
Organization	Danko Martincic
Address	1641 E Polston Ave Ste 102
City	Post Falls
State	ID
ZIP	83854
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	May 18, 2006

Payer Source	Total Paid
Medicare	$2.6M
Medicaid	$0

Key Findings

DANKO MARTINCIC is a Hematology & Oncology physician enumerated on 2006-05-18 (~20 years ago) with $2.6M in total Medicare revenue on file and no Medicaid billing recorded (none). This profile indicates a long-tenured outpatient oncology practice that is effectively single-payer in the claims data provided, with Medicare representing the entirety of reported public-payer revenue.

Revenue concentration is highly focused: the precomputed top three Medicare codes account for 78.1% of this provider's total Medicare revenue. Those top drivers are J9299 $967.9K (38.1%), J9271 $767.6K (30.2%), and J9228 $249.6K (9.8%), which together dominate the revenue mix and point to a narrow set of high-cost injectable therapies underpinning billing.

The code mix (large volumes of J9299, J9271 and J9228 alongside chemotherapy administration codes such as 96413 and infusion add-ons like 96417) signals an operation built around oncology infusions and immune checkpoint inhibitor administration. High-volume biologic and chemotherapy administration plus significant E/M activity suggests the practice combines drug administration with ongoing complex outpatient management of oncology patients.

J9299 (nivolumab) is a standout: $967.9K in revenue (38.1% of the provider's Medicare revenue) and ranked #20 of 505 providers nationally (96th percentile; notably above typical national volume for this code). This positioning indicates the provider is a major national administrator of nivolumab relative to peers and that nivolumab treatment is a primary revenue engine for the practice.

J9271 (pembrolizumab) and J9228 (ipilimumab) show contrasting competitive signals: J9271 produced $767.6K (30.2%) and ranks #383 of 1841 (79th percentile; typical, unremarkable volume) indicating moderate but not exceptional pembrolizumab activity, while J9228 generated $249.6K (9.8%) and ranks #9 of 12 (27th percentile; typical, unremarkable volume), reflecting much lower national participation in ipilimumab relative to the provider’s other checkpoint therapies. Together these ranks imply the practice emphasizes certain immunotherapies unevenly rather than uniformly high volume across all checkpoint inhibitors.

Evaluation-and-management coding shows an outsized footprint for high-complexity visits: 99215 contributed $130.8K (5.1%) and is ranked #252 of 145531 providers nationally (100th percentile; extreme outlier), and 99214 produced $66.2K (2.6%) and ranks in the 95th percentile. Those placements suggest the provider manages a large panel of complex established oncology patients and bills a high rate of top-level outpatient E/M visits relative to national peers.

Infusion and chemotherapy administration activity is elevated across multiple procedure codes: 96413 is $74.1K (2.9%) and ranks #172 of 7514 (98th percentile; notably above typical national volume) and 96417 is $14K (0.6%) and ranks in the 98th percentile. The combination of high percentiles on core chemotherapy administration codes and the dominant checkpoint-inhibitor drug codes indicates substantial infusion throughput and operational capacity for administering complex oncology regimens.

Absence of Medicaid billing (none below) means the provider’s publicly reported volume is concentrated in Medicare, exposing revenue profile to Medicare utilization and pricing dynamics rather than a diversified public-payer mix. For analysts, this single-payer concentration increases sensitivity to Medicare policy and beneficiary shifts and suggests limited engagement with the Medicaid population in the available claims data.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

47 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9299	Injection, nivolumab, 1 mg	46,090	$20	$967.9K
J9271	Injection, pembrolizumab, 1 mg	20,200	$40	$767.6K
J9228	Injection, ipilimumab, 1 mg	3,160	$80	$249.6K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	1,010	$130	$130.8K
J0897	Injection, denosumab, 1 mg	5,340	$20	$96.1K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	810	$90	$74.1K
Q5119	Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg	2,910	$20	$66.9K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	750	$90	$66.2K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	80	$340	$28.2K
96417	In this add–on procedure, the provider continues administration of a chemotherapy drug into a vein using an infusion technique. He uses this code to report administration of a different chemotherapy…	310	$50	$14K

Showing 1–10 of 47

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 47 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Idaho Distribution

Danko Martincic — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Idaho

Full comparison — all codes billed, vs. state median

47 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9299	1	10	41,440	$20	$687.9K
J9271	1	10	12,400	$40	$469.8K
J9228	1	10	3,160	$80	$248.6K
J3490	3	10	230	$880	$174.8K
J0897	7	30	2,580	$20	$76.2K
Q5119	3	10	3,200	$20	$71.3K
J1454	2	10	120	$340	$39.9K
96413	2	20	250	$90	$26K
99214	42	2,690	90	$70	$10.4K
96365	9	20	80	$40	$7.4K

Showing 1–10 of 47

Related Providers

Other providers that share a Tax Identification Number (TIN) with Danko Martincic, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Sunnyside Community Hospital Association	WA	Critical Access Hospital	$0	$55.1M
Marion Area Physicians LLC	OH	Internal Medicine Physician	$0	$15.7M
Shc Medical Center Toppenish	WA	General Acute Care Hospital	$0	$15.1M
Sunnyside Community Hospital Association	WA	Rural Health Clinic/Center	$0	$7M
Shc Medical Center - Yakima	WA	General Acute Care Hospital	$0	$6.9M
Sunnyside Community Hospital Association	WA	Rural Health Clinic/Center	$0	$5.8M
Shc Medical Center Toppenish	WA	Rural Health Clinic/Center	$0	$5M
St. Joseph Hospital LLC	ID	General Acute Care Hospital	$0	$4.7M
Sunnyside Community Hospital Association	WA	Rural Health Clinic/Center	$0	$4.4M
David Bartels	ID	Hematology & Oncology Physician	$3.5M	$0

Nearby Providers

Other providers in the same ZIP code as Danko Martincic, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Dirne Health Centers, Inc.	ID	Federally Qualified Health Center (FQHC)	$0	$6.3M
Kootenai County	ID	Local Education Agency (LEA)	$0	$5.2M
Learning Garden Developmental Preschool	ID	Developmentally Disabled Services Day Training Agency	$0	$3.1M
Aaging Better In-home Care, LLC	ID	Home Health Agency	$0	$2.4M
Little Smiles Pediatric Dentistry PC	ID	Pediatric Dentistry	$0	$2.2M
North Idaho Day Surgery LLC	ID	General Acute Care Hospital	$0	$1.2M
Pleasant View Surgery Center, LLC	ID	Ambulatory Surgical Clinic/Center	$1M	$0
Corbin Jacobs	ID	Radiation Oncology Physician	$915.1K	$0
Tandy Therapy LLC	ID	Speech-Language Pathologist	$0	$780.1K
Post Falls Asc, L.L.C.	ID	Ambulatory Surgical Clinic/Center	$0	$734K

Danko Martincic — Billing Profile & Reimbursement Data

Sign up for Danko Martincic — Billing Profile & Reimbursement Data policy alerts

Danko Martincic — Billing Profile & Reimbursement Data

Sign up for Danko Martincic — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References